MAC
62
-13
KIM
58
7
HP
52
8
A
37
13
GME
71
6
NSC
51
3
WU
30
2
VRSK
77
-7
BEN
52
4
INTU
74
4
IRM
76
-5
PNC
55
7
ETR
49
-3
DFS
65
8
KMB
36
-3
SLG
73
-4
HBI
49
-10
MA
55
-3
PDCO
55
-3
UHS
51
-3
MAC
62
-13
KIM
58
7
HP
52
8
A
37
13
GME
71
6
NSC
51
3
WU
30
2
VRSK
77
-7
BEN
52
4
INTU
74
4
IRM
76
-5
PNC
55
7
ETR
49
-3
DFS
65
8
KMB
36
-3
SLG
73
-4
HBI
49
-10
MA
55
-3
PDCO
55
-3
UHS
51
-3
Financhill
Back

Autolus Therapeutics PLC 10K Form

Sell
24

AUTL
Autolus Therapeutics PLC

Last Price:
3.42
Seasonality Move:
-14.93%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AUTL News And Ratings

See the #1 stock for the next 7 days that we like better than AUTL

AUTL Financial Statistics

Sales & Book Value

Annual Sales: $1.7M
Cash Flow: $-41.05M
Price / Cash Flow: 0
Annual Sales: $2.19
Price / Book: 1.59

Profitability

EPS (TTM): -1.21000
Net Income (TTM): $-221.26M
Gross Margin: --
Return on Equity: -80.74%
Return on Assets: -42.65%

Autolus Therapeutics PLC Earnings Forecast

Key Autolus Therapeutics PLC Financial Ratios

  • The Research & Development expenses have been 7,684.39% of Revenue.
  • The Interest Expense is -21.63% of Operating Income.
  • The Net Earning history of AUTL is -12,272.26% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 5 years.

Autolus Therapeutics PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AUTL
CUSIP: 05280R
Website: autolus.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 18.29
Quick Ratio: 17.97

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AUTL Technical Analysis vs Fundamental Analysis

Sell
24
Autolus Therapeutics PLC (AUTL) is a Sell

Is Autolus Therapeutics PLC a Buy or a Sell?